Denali monetises its FDA voucher as AVLAYAH enters a critical confirmatory phase
Denali Therapeutics is converting AVLAYAH’s regulatory reward into non-dilutive capital for its blood-brain barrier pipeline, but clinical and commercial risks remain.
Pharma & Biotech